RGC as reported
- Net Income
- −$3.6M
Net Income · −17% year on year · trailing twelve months to FY2025
- Free Cash Flow
- −$3.3M
Free Cash Flow · −18% year on year · trailing twelve months to FY2025
- EPS
- −$0.72
EPS · −17% year on year · trailing twelve months to FY2025
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Net Income | −$3.6M | −17% | FY2025 |
| EPS | −$0.72 | −17% | FY2025 |
| ROE | −74% | n/a | FY2025 |
| ROA | −62% | n/a | FY2025 |
| Free Cash Flow | −$3.3M | −18% | FY2025 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Regencell Bioscience Holdings Limited (RGC) - Net IncomeNet IncomeRegencell Bioscience Holdings Limited (RGC)
Drug Manufacturers - Specialty & Generic
Ranks #27 of 29 by Smart Score